The U.S. FDA has approved Kymriah® (tisagenlecleucel – Novartis) to treat relapsed or refractory follicular lymphoma in adults who have already received at least two lines of systemic therapy.
- Fist FDA approved in 2017, Kymriah is also indicated to treat:
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse in patients up to 25 years; and
- Relapsed or refractory large B-cell lymphoma in adults who have already received at least two lines of systemic therapy.
- Kymriah is a CAR-T therapy produced using the patient’s own immune. The cells are modified in a lab to specifically target cancer. For follicular lymphoma in adults, the recommended dose is 0.6 to 6.0 x 108 CAR-positive viable T cells.
